|
Arris bought Sequana to give them a platform technology in disease gene identification and functional genomics. Remember that the purchase of Sequana was for approximately 14 million shares of Arris. In return, they received approximately $50 to $55 milion in cash on Sequana's books, a new agreement which was announced the day of the merger with Parke Davis which has the potential for up to $103 million in revenues over a five year period. In particular, I believe Arris was very interested in Sequana's cancer partnership with Memorial Sloane Kettering. They have 24 scientists working at Sequana, and at the luncheon on November 2nd, Kerin Kinsella, CEO of Sequana, said some important announcements could come over the next few months from their research. Thus, all in all, I would say this was a very cheap acquisition, and am especially pleased with John Walker being CEO of the combined company which I think is nothing but very good news. I doubt if the stock goes any lower in here, but who knows how bad the market will get. All told, I think we are at an unbelievable buying point, and all should be rewarded from these levels. |
